BACKGROUND: Respiratory muscle function in patients with cystic fibrosis (CF) has been studied by measurement of maximal inspiratory pressure (P Imax ), maximal expiratory pressure (P Emax ), and the pressure-time index of the respiratory muscles (PTI mus ). The maximum rate of pressure development (MRPD) during P Imax (MRPD-P Imax ), MRPD during P Emax (MRPD-P Emax ), maximal relaxation rate (MRR) during P Imax (MRR-P Imax ), and MRR during P Emax (MRR-P Emax ) have not been studied in CF. Our aim was to study MRPD and MRR and investigate their possible application as accessory indices of respiratory muscle function in patients with CF. METHODS: FEV 1 , FVC, and maximal expiratory flow between 25% and 75% of vital capacity, body mass index (BMI), upper arm muscle area, P Imax , P Emax , PTI mus , MRPD-P Imax , MRPD-P Emax , MRR-P Imax , and MRR-P Emax were assessed in 123 CF patients and in a control group of 123 healthy subjects matched for age and sex. RESULTS: MRR-P Emax was significantly increased and MRPD-P Emax was significantly decreased in the CF patients, compared to the healthy controls. In the CF patients MRR-P Imax was significantly related to PTI mus (P ‫؍‬ .02), FEV 1 (P ‫؍‬ .03), FVC (P ‫؍‬ .001), BMI (P < .001), and upper arm muscle area (P < .001). In the CF patients, MRPD-P Imax and MRPD-P Emax were significantly related to upper arm muscle area (P < .001), BMI (P < .001 and P ‫؍‬ .01, respectively), P Imax (P < .001), and P Emax (P < .001). CONCLUSIONS: The CF patients exhibited increased MRR and decreased MRPD during maximal respiratory effort, compared to controls. The differences in MRR-P Imax and MRPD-P Imax between the controls and the complete group of CF patients were not significant. MRPD and MRR were significantly related to nutritional and pulmonary function impairment in CF patients. MRPD strongly correlated to maximal respiratory muscle pressures, and MRR strongly correlated to PTI mus in patients with CF. These findings suggest that CF patients are at increased risk of respiratory muscle fatigue. Regular determination of MRPD and MRR may be clinically useful in CF patients and help to initiate inspiratory muscle training and noninvasive ventilation.
Introduction
Respiratory muscle function in cystic fibrosis (CF) has been studied utilizing a wide variety of methods and indices. Maximal inspiratory pressure (P Imax ) and maximal expiratory pressure (P Emax ) have been used to describe properties of respiratory muscle strength, 1,2 while the noninvasive pressure-time index of the respiratory muscles (PTI mus ) has also been applied to describe respiratory muscle function. 3, 4 Chronic obstruction and hyperinflation, manifested by affected pulmonary function indices, might contribute to impaired respiratory muscle function in patients with CF, 5, 6 while chronic malnourishment might be associated with decreased respiratory muscle strength. 4, 7 Other factors that impact respiratory muscle function in CF include chronic inflammation, lung parenchymal damage, and the direct effects of hypoxemia and hypercapnia on muscle function. 8 The maximum rate of pressure development (MRPD) during the initial linear incline of the P Imax curve has been used to assess respiratory muscle function. 9 MRPD has been studied in healthy adult individuals as a means to assess the effect of inspiratory muscle training on inspiratory muscle function. 10 Furthermore, decreases in relaxation rate of skeletal muscles upon cessation of contraction are generally recognized to describe muscle fatigue as a result of reduced calcium uptake. 11 Slowing in the rate of decline of inspiratory pressure, as demonstrated by decrease of the maximum relaxation rate (MRR), is an accepted and reliable index of respiratory muscle fatigue. 11 Inspiratory muscle MRR can be assessed noninvasively by measuring the MRR at the nose during a sniff nasal inspiratory pressure maneuver. 11, 12 The increased work load faced by the respiratory muscles due to airway obstruction, hyperinflation, and suboptimal nutrition places the respiratory muscles in patients with CF in mechanical disadvantage and predisposes CF patients to respiratory muscle fatigue and respiratory failure. 13 Indices that describe respiratory muscle function have been found to be affected in CF. 3, 4 To our knowledge, MRPD and MRR have not been previously studied in patients with CF.
Our hypothesis was that MRR and MRPD would be decreased in patients with CF, compared to healthy controls, during maximal static respiratory pressure maneuvers. The objective of this study was thus to compare MRR and MRPD during maximal static respiratory pressure maneuvers in CF patients and healthy individuals. Secondary aims were to assess possible relation of these indices to well established indices of respiratory muscle function such as maximal respiratory pressures and PTI mus , as well as to establish possible contributions of nutrition and pulmonary function impairment to MRR and MRPD in patients with CF.
Methods

Subjects
CF patients attending the Department of Cystic Fibrosis of Aghia Sophia Children's Hospital in Athens, Greece, for regular evaluation were investigated. This department follows some patients into adulthood, and subjects were included irrespective of age. The control group consisted of healthy children and young adults with no history of respiratory disease matched for age and sex and enrolled at the pediatric department of the University Hospital of Patras, Greece. CF diagnosis was made by abnormal sweat test results and confirmed with expanded mutation analysis. 14 Patients with exacerbation during the past month, on steroid therapy, or with coexisting pulmonary pathology were excluded from the study. Children younger than 6 years old were excluded from the study, as they were unable to perform the necessary pulmonary function and respiratory muscle function maneuvers. Standard chest physical therapy was undertaken by all CF patients. The study protocol was approved by the hospital's ethics committee. Caregivers, or subjects when appropriate, provided informed written consent prior to the study, while consent was also sought and obtained from older children and adolescents.
Measurements
Maximal Relaxation Rate and Maximum Rate of Pressure Development
MRR and MRPD were assessed during maximal inspiratory and maximal expiratory efforts against an occluded airway, using a handheld respiratory pressure meter (MicroRPM, CareFusion, San Diego, California). MRR was calculated as the first derivative of pressure with respect to time over the first half of the relaxation curve 11 and expressed as a percentage of the pressure fall in 10 ms. 12 MRPD was assessed and defined as the positive peak of
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Current knowledge
In patients with cystic fibrosis, pathophysiologic disturbances in pulmonary function and chronic malnourishment lead to respiratory muscle dysfunction, which is commonly quantified by measurement of the maximal inspiratory and expiratory pressures.
What this paper contributes to our knowledge
The maximal rate of pressure development and maximal relaxation rate during measurement of maximal inspiratory pressure in subjects with cystic fibrosis were significantly different from normal subjects. Larger differences in the maximal rate of pressure development and maximal relaxation rate were strongly associated with nutritional and pulmonary dysfunction. These measurements may play a role in monitoring cystic fibrosis patients.
the pressure derivative as a function of time during the initial incline of the maximal respiratory pressure curve. 10 
Measurement of Respiratory Pressures
Flow was measured with a pneumotachograph (Mercury F100L, GM Instruments, Kilwinning, Scotland) connected to a differential pressure transducer (DP45, range Ϯ 3.5 cm H 2 O, Validyne Engineering, Northridge, California). Airway pressure was recorded from a side port on the pneumotachograph, connected to a differential pressure transducer (DP45, range Ϯ 225 cm H 2 O, Validyne Engineering, Northridge, California). From the differential pressure transducers the signals were amplified (CD280, Validyne Engineering, Northridge, California), recorded, and displayed with data analysis software (Labview, National Instruments, Austin, Texas) with analog-to-digital sampling at 100 Hz (16-bit NI PCI-6036E, National Instruments, Austin, Texas). P Imax , P Emax , airway-occlusion pressure at 0.1 s after the start of inspiration (P 0.1 ), breathing frequency, tidal volume (V T ), minute ventilation, inspiratory time (T I ), total time of respiration (T tot ), and T I /T tot were measured. P 0.1 was calculated as the airway pressure 0.1 s after an occlusion while the subject was quietly breathing. Five airway occlusions were performed, and the average value for P 0.1 value was calculated. P Imax was measured at residual volume against an occluded airway upon a maximal inspiratory effort. 15 P Emax was measured at total lung capacity against an occluded airway upon a maximal expiratory effort. 15 Both P Imax and P Emax were measured on the basis of 5 maximal reproducible respiratory efforts, and the maximum achieved value was recorded. A small needle leak in the respiratory circuit allowed for avoidance of glottic closure and falsely elevated pressure recordings. 11 A unidirectional valve (total dead space 8 mL) attached to the rubber mouthpiece was used to perform the occlusions. Care was taken to eliminate any leak around the mouthpiece. Only P Imax and P Emax maneuvers with plateau pressure for at least 1 s were accepted for subsequent analysis. 11
Calculation of Pressure-Time Index of the Respiratory Muscles
PTI mus was calculated as:
where P Imean is for the average airway pressure during inspiration, derived from the formula P Imean ϭ 5 ϫ P 0.1 ϫ T I , P Imax is the maximum inspiratory airway pressure, T I is the inspiration time, and T tot is the total time for each breath, calculated from the airway flow signal. 4, 16, 17 Lung Function Tests FEV 1 , maximal expiratory flow between 25% and 75% of vital capacity (MEF 25-75% ), and FVC were measured (MasterScreen, Jaeger/CareFusion, San Diego, California). The pulmonary function tests were performed according to European Respiratory Society guidelines 18 and are expressed as percentage of normal values (% predicted). 19 The limits utilized for the staging of pulmonary function tests were based on the pulmonary function score developed by Cropp et al. 5 
Nutritional Parameters
Body mass index (BMI) was calculated as the body weight of the individual in kilograms, divided by the square of his height in meters. 20 The BMI z-score method was used for subjects ages 6 -19 years, while for individuals older than 20 years the BMI method was used. 21 Mid-arm muscle circumference (MAMC) was measured to the nearest centimeter, midway between the tip of the acromion and the olecranon process, with the right hand hanging relaxed. 22 Triceps skinfold thickness (TST) was measured to the nearest millimeter, halfway over the triceps muscle (Harpenden Skinfold Caliper, Baty International, West Sussex, United Kingdom) with the skinfold parallel to the longitudinal axis of the arm. 22 From these indices upper arm muscle area (UAMA) was calculated. 23 
Statistics
Data were assessed for normality with the application of the Kolmogorov-Smirnoff and Shapiro-Wilk tests. Differences between groups were assessed for significance with the Mann-Whitney rank sum test. Linear regression analysis was used to examine the relation of MRPD and MRR to PTI mus , P Imax and P Emax and the relation of MRPD and MRR to FEV 1 , MEF 25-75% , FVC, UAMA, BMI, and BMI z-score. Variables without normal distribution were logarithmically transformed. Statistical analysis was performed using statistics software (SPSS 17.0, SPSS, Chicago, Illinois).
Results
Between November 2009 and September 2010, 123 subjects were included in the study. The control group consisted of 123 healthy individuals matched as possible for age and sex. Ages ranged from 6 to 34 years.
Nutritional parameters such as weight, height, and BMI did not achieve significant differences between the CF and the control groups, while BMI z-score was significantly lower in the CF group, compared to the control group (Table 1) . MAMC, TST, and UAMA were found to achieve significantly lower values in the CF subjects, compared to the healthy controls (see Table 1 ).
Breathing cycle components in the CF subjects and controls are presented in Table 1 . Breathing frequency, T I , T tot , and T I /T tot were not significantly different between the subjects and controls, while V T , minute ventilation and V T /T I were all significantly decreased in the CF group, compared to the controls. V T /kg was not significantly different between the CF subjects and the control group (see Table 1 ).
Respiratory muscle strength parameters such as P Imax and P Emax were significantly decreased in the CF group, compared to the control group, while P Imean /P Imax and PTI mus were significantly prolonged in CF subjects compared to healthy controls (see Table 1 ). P 0.1 and P Imean failed to achieve significant difference between the subject and control groups. 25-75% ϭ maximal expiratory flow between 25% and 75% of vital capacity T I ϭ inspiratory time T tot ϭ total time of respiration P 0.1 ϭ airway-occlusion pressure 0.1 s after the start of inspiratory flow P Imean ϭ inspiratory pressure P Imax ϭ maximal inspiratory pressure PTI mus ϭ pressure time index of the respiratory muscles P Emax ϭ maximal expiratory pressure MRR-P Imax ϭ muscle relaxation rate during maximal inspiratory pressure maneuver MRPD-P Imax ϭ maximum rate of pressure development during maximal inspiratory pressure maneuver MRR-P Emax ϭ muscle relaxation rate during maximal expiratory pressure maneuver MRPD-P Emax ϭ maximum rate of pressure development during maximal expiratory pressure maneuver MRPD-P Emax was significantly decreased and MRR-P Emax was significantly increased in the CF group, compared to the control group (Fig. 1) , while MRPD-P Imax and MRR-P Imax were not significantly different (see Table 1 ).
Dividing the CF cohort according to pulmonary function values produces the data presented in Table 2 . CF subjects with decreased FEV 1 values, compared to CF subjects with normal or less affected FEV 1, are found to achieve significantly lower MRPD-P Emax but not significantly different MRPD-P Imax , while MRR was not significantly different in these groups, regardless of whether the maneuvers were performed during maximal inspiration or expiration. The CF subjects with affected FVC had significantly increased MRR-P Imax (Fig. 2) but not significantly different MRR-P Emax , MRPD-P Imax , or MRPD-P Emax compared to the CF subjects with normal or less affected FVC. The CF subjects with affected MEF 25-75% failed to exhibit any significant difference in MRR or MRPD upon maximal inspiration or maximal expiration, compared to the CF subjects with normal or less affected MEF 25-75% .
In the CF group there was a significant negative relation between MRR-P Imax and weight (r ϭ Ϫ0.46, P Ͻ .001), height (r ϭ Ϫ0.44, P Ͻ .001), and BMI (r ϭ Ϫ0.37, P Ͻ .001), but not between MRR-P Imax and BMI z-score. MRR-P Imax in CF subjects was significantly negatively related to MAMC (r ϭ Ϫ0.43, P Ͻ .001), TST (r ϭ Ϫ0.23, P ϭ .01), and UAMA (r ϭ Ϫ0.33, P Ͻ .001), as well as to FEV 1 (r ϭ Ϫ0.20, P ϭ .03) and FVC (r ϭ Ϫ0.30, P ϭ .001). There was a significant positive relation in the CF subjects between MRR-P Imax and PTI mus (r ϭ 0.22, P ϭ .02), but no significant relation was demonstrated between MRR-P Imax and P Imax or P Emax .
MRPD-P Imax in CF subjects was significantly positively related to weight (r ϭ 0.47, P Ͻ .001), height (r ϭ 0.41, P Ͻ .001), BMI (r ϭ 0.36, P Ͻ .001), MAMC (r ϭ 0.38, P Ͻ .001), and UAMA (r ϭ 0.47, P Ͻ .001), but not to BMI z-score or TST. No significant relation was established in the CF subjects between MRPD-P Imax and FEV 1 , MEF 25-75% , or FVC. There was a significant positive relation in the CF subjects between MRPD-P Imax and P Imax (r ϭ 0.64, P Ͻ .001), and between MRPD-P Imax and P Emax (r ϭ 0.43, P Ͻ .001), but not between MRPD-P Imax and PTI mus .
MRR-P Emax in the CF subjects was significantly negatively related to height (r ϭ Ϫ0.22, P ϭ .013), but not to weight, BMI, BMI z-score, MAMC, TST, UAMA, FEV 1 , MEF 25-75% , FVC, P Imax , P Emax , or PTI mus .
MRPD-P Emax in the CF subjects was significantly positively related to height (r ϭ 0.36, P Ͻ .001), weight (r ϭ 0.41, P Ͻ .001), BMI (r ϭ 0.30, P ϭ .01), MAMC (r ϭ 0.34, P Ͻ .001), UAMA (r ϭ 0.45, P Ͻ .001), P Imax (r ϭ 0.65, P Ͻ .001), and P Emax (r ϭ 0.52, P Ͻ .001) but not to TST, FEV 1 , MEF 25-75% , FVC, and BMI z-score. MRPD-P Emax was also found to achieve a significant negative relation with PTI mus (r ϭ Ϫ0.24, P ϭ .007).
Discussion
This study demonstrated that MRR is increased and MRPD is decreased during maximal expiration in CF subjects, compared to healthy controls. In the CF subjects, MRR-P Imax , MRPD-P Imax , and MRPD-P Emax were significantly related to UAMA and anthropometric indices such as weight, height, and BMI. Only MRR-P Imax was significantly related to FEV 1 and FVC in CF subjects. In the CF group, MRR-P Imax and MRPD-P Emax were significantly related to PTI mus , while MRPD-P Imax and MRPD-P Emax were both significantly related to P Imax and P Emax .
Our results suggest that respiratory muscle function is compromised in patients with CF and that these patients are at increased risk of respiratory muscle fatigue. Factors that determine MRR and MRPD in CF patients might include airway obstruction and poor nutrition. These findings highlight the role of airway disease and undernutrition in the pathogenesis of respiratory muscle fatigue and respiratory failure in patients with CF.
Analysis of respiratory muscle function by means of MRPD has been studied in the scope of investigating the effect that inspiratory muscle training has on respiratory muscle function. 9 Inspiratory muscle training in healthy males produced a significant rise in MRPD. 24 10 Our study reports lower MRPD values, compared to the previously published studies, 10, 24 which, given the differences in the age groups, is not a surprising finding. No data exist in the literature reporting MRPD values in the pediatric population or in CF patients, precluding the possibility of comparing our data to data derived from a similar population. MRPD-P Emax was decreased in CF patients with decreased FEV 1 , as compared to CF patients with normal or less affected FEV 1 , to a level that just reached statistical significance. MRPD-P Emax and MRPD-P Imax were both significantly related to maximal respiratory pressures in CF patients, while MRPD-P Emax and MRPD-P Imax were also found to achieve a significant relation to weight, height, BMI, MAMC, and UAMA underlying the well reported relation of malnutrition and respiratory muscle compromise in CF. 2, 4 Furthermore, the significant negative relation of MRPD-P Emax to PTI mus in CF patients might reflect the balance disruption between the respiratory load and neuromuscular competence that has been described in CF patients. 13 MRR can be invasively measured with 2 balloon catheters measuring esophageal and gastric pressures and thus obtaining the transdiaphragmatic pressure and the corresponding MRR, which is calculated as the first derivative of pressure over time during the first half of the relaxation curve. 11 Transdiaphragmatic MRR has been shown to slow post induced fatigue in healthy young men. 25 Mulvey et al 26 studied sniff MRR at esophageal and transdiaphragmatic pressures and concluded that MRR became faster at sniff peak pressures that exceeded 10% of an individual's maximal pressure. Comparison of MRR following short, sharp inspiratory efforts against an occluded airway (mouth) or unoccluded nostril concluded that the unoccluded nostril method produced more consistent and quantitatively greater MRR changes, as compared to the occluded mouth method. 27 Kyroussis et al introduced the concept of measuring MRR noninvasively at the level of the nostrils during unoccluded sniff of increasing intensity reaching maximal effort, as nasal MRR was found to reflect esophageal MRR over a wide range of sniff pressures. 12 Our study examined MRR after a maximal static inspiratory and expiratory effort against an occluded airway. Although MRR-P Emax was significantly increased in CF patients, compared to healthy controls, this index in CF patients was not related to pulmonary function indices or nutritional indices, with the exception of height. Furthermore, abdominal muscle recruitment is known to occur during active forced expiration, and air-flow obstruction is associated with prolonged expiration, further diminishing 25-75% ϭ maximal expiratory flow between 25% and 75% of vital capacity MRR-P Imax ϭ muscle relaxation rate during maximal inspiratory pressure maneuver MRPD-P Imax ϭ maximum rate of pressure development during maximal inspiratory pressure maneuver MRR-P Emax ϭ muscle relaxation rate during maximal expiratory pressure maneuver MRPD-P Emax ϭ maximum rate of pressure development during maximal expiratory pressure maneuver the possible utility of this index in describing respiratory muscle function. MRR-P Emax is a global index that does not differentiate the relative contributions of the respiratory and abdominal muscles in forced expiration. The fact that MRR-P Emax was significantly increased in the CF subjects, compared to controls, might represent a selective training effect that CF lung disease imposes on the abdominal muscles, as it is well known that airway obstruction promotes active expiration and abdominal muscle recruitment. MRR-P Imax was significantly related to FEV 1 , FVC, as well as height, weight, BMI, MAMC, TST, and UAMA in CF. Additionally, the CF subjects with decreased FVC were found to attain slower MRR values, as compared to the CF subjects with normal or less affected FVC. Affected pulmonary function and poor nutrition have previously been associated with respiratory muscle function compromise in subjects with CF in studies that utilized different indices to assess respiratory muscle function, such as maximal pressures 2 and PTI mus . 3, 4 Furthermore, decreased FEV 1 has been associated with increased elastic load and work of breathing in CF patients. 28 The association of respiratory muscle function to nutritional indices, and namely indices that describe muscular state, such as MAMC and UAMA, has been highlighted in previous studies, 4 while respiratory muscle strength has been found to correlate significantly to limb muscle strength. 1, 29 Although MRR attains significantly different values between patients and controls, as well as between CF patients of different spirometric severity, this finding appears blunted by the limited number of integer values that this index attains.
MRR and MRPD during P Imax were not significantly different between CF and healthy controls, which might partially reflect the fact that our patient population was found as a whole not to suffer from severe airway obstruction (median FEV 1 was 100.3% of predicted).
Our study reports significantly higher PTI mus and significantly lower P Imax and P Emax values in CF subjects, compared to healthy controls. This observation is in agreement with previous studies that investigated these indices in CF patients. 1, 3, 4 Indices that describe respiratory drive, such as P 0.1 and breathing frequency, were not significantly different between the CF group and the controls, probably reflecting the relatively good pulmonary condition of our CF cohort (median FEV 1 was 100.3% of predicted) with the exception of V T /T I , which nevertheless is not corrected for weight. V T /kg was not significantly different in the CF subjects, compared to the control group. Nutrition indices such as MAMC, TST, UAMA, and BMI z-score were significantly lower in the CF subjects, compared to the healthy controls, and this is in accordance with previously published data, 3, 4 while weight, height, and BMI failed to reach statistically significant difference between the 2 groups.
Evaluation of respiratory muscle function by MRPD and MRR bears the advantage that it can be easily performed at the bedside with a portable handheld device. Our findings on MRPD and MRR in subjects with CF bear potential clinical implications. Decision to initiate inspiratory muscle training of variable intensity can be decided on the basis of the values that these indices attain, reflecting different levels of severity of respiratory muscle compromise and highlighting the potential danger of respiratory muscle fatigue. MRR and MRPD can also be used to aid the decision on initiating noninvasive ventilation with a view to improve gas exchange, preserve respiratory muscle function, and prevent or treat respiratory exacerbations. 13 Further research on the effect of inspiratory muscle training and aerobic exercise on MRPD and MRR, and on the association of these indices with adverse clinical outcomes, might be of particular clinical interest.
Our study has some limitations that need to be considered. Measurement of MRR was performed during a maximal static respiratory maneuver. MRR has been shown to be effort dependent, and MRR becomes progressively faster at higher pressures as fast twitch type-II muscle fibers are progressively activated. 26 Furthermore, maximal effort is more likely to recruit abdominal, upper airway, and neck muscles, resulting this way in a faster MRR, which does not necessarily reflect inspiratory muscle function. 30 On the other hand, and given these limitations, MRR has been applied as a measure to assess respiratory muscle fatigue both after a maximal effort 12, 25 as well as against an occluded airway. 25, 27 Another limitation of the study might be that the investigated CF subjects suffered as a whole relatively mild airway disease, as demonstrated by the aforementioned median pulmonary function indices, thus restricting the possibility to identify parameters associated with poor respiratory muscle function.
Conclusions
In conclusion, this study demonstrated that CF patients exhibit significantly increased MRR-P Emax and significantly lower MRPD-P Emax values, compared to the general population. MRPD was significantly related to BMI and UAMA, while MRR-P Imax was significantly related to FEV 1 , FVC, BMI, and UAMA, underlying the contribution of compromised nutrition and pulmonary function to impaired respiratory muscle function. The significant positive relation of MRPD to maximal respiratory pressures and of MRR-P Imax to PTI mus might indicate a possible utility of these indices as accessory tools in the assessment of respiratory muscle function in CF patients. Application of measurement of MRPD and MRR in clinical practice might facilitate making decisions on initiation of treatment modalities such as noninvasive ventilation and inspiratory muscle training.
